MedPath

PharmAla to Supply University of Texas, San Antonio, with Novel MDMA Dosage Form for Clinical Trial

• PharmAla Biotech has been contracted to supply LaNeo™ MDMA to the University of Texas, San Antonio, for a clinical trial. • The collaboration aims to develop and test a novel dosage form of LaNeo™ MDMA in an investigator-initiated human clinical trial. • PharmAla's CEO, Nicholas Kadysh, expressed the company's readiness to support researchers with various MDMA dosage forms and delivery models. • PharmAla also announced the publication of a patent application related to potential uses of its APA-01 novel molecular entity.

PharmAla Biotech Holdings Inc. will supply the University of Texas, San Antonio, with LaNeo™ MDMA for a proposed clinical trial. The collaboration aims to create and test a novel dosage form of LaNeo™ MDMA in an investigator-initiated human clinical trial.

Supporting Innovative Research

Nicholas Kadysh, CEO of PharmAla Biotech, stated the company is prepared to support researchers with its existing API and 40mg capsules, as well as in the development of new dosage forms for LaNeo™ MDMA. He noted that while the current 40mg dose is suitable for many assisted therapy use-cases, PharmAla is open to partnering with researchers exploring different doses and drug delivery models.

Patent Publication

PharmAla also announced the publication of a patent application by the USPTO related to the potential uses of PharmAla’s APA-01 novel molecular entity. This application is a divisional application arising from PharmAla’s original APA-01 patent, which was granted earlier this year as US Patent #12,042,428.
Dr. Harpreet Kaur, VP of Research at PharmAla Biotech, thanked IPON for their support in the company's global patent filings. She emphasized the importance of keeping this valuable IP in Canada.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Grants Priority Review to Saol Therapeutics' SL1009 for Rare Pediatric Mitochondrial Disorder

The FDA has accepted Saol Therapeutics' NDA for SL1009 (sodium dichloroacetate) with Priority Review for treating Pyruvate Dehydrogenase Complex Deficiency (PDCD).
SL1009, an oral solution, targets PDK to enhance ATP production in PDCD patients and has Orphan Drug, Fast Track, and Rare Pediatric Disease Designations.

PharmAla to Supply MDMA for Clinical Trial in Exchange for Data License

PharmAla Biotech has reached an agreement in principle to supply its LaNeo™ MDMA to a research institution for use in a clinical trial.
In exchange for providing LaNeo™ MDMA, PharmAla will receive a full and perpetual license to the efficacy and safety data generated by the trial.

PharmAla Biotech to Supply LaNeo MDMA for Yale University Clinical Trial

PharmAla Biotech has been contracted to supply its LaNeo MDMA for a clinical trial at Yale University, marking continued recognition in academic research.
The company offers researchers a tool providing access to drug product quality information to facilitate clinical trial registrations and IRB approvals.

Neurizon Therapeutics Repurposes Monepantel for MND Treatment in Healey ALS Platform Trial

Neurizon Therapeutics (formerly PharmAust) is repurposing monepantel, an existing animal drug, for the treatment of motor neuron disease (MND).
Monepantel inhibits the mTOR signaling pathway and stimulates autophagy, potentially slowing MND progression and increasing life expectancy.

UT Health San Antonio Receives $12 Million to Advance Opioid Use Disorder Drug

UT Health San Antonio has been awarded $12 million to develop methocinnamox (MCAM) for opioid use disorder.
MCAM, a mu opioid receptor antagonist, blocks the effects of opioids like fentanyl, heroin, and oxycodone.

PharmAust Advances ALS Treatment with New Funding

PharmAust has issued new shares to raise capital, supporting the clinical development of Monepantel (MPL).
MPL is currently being investigated for its potential to slow the progression of Amyotrophic Lateral Sclerosis (ALS).

PharmAust Seeks European Orphan Drug Designation for Monepantel in ALS Treatment

PharmAust has applied for Orphan Medicinal Product Designation (OMPD) from the EMA for monepantel (MPL) to treat amyotrophic lateral sclerosis (ALS).
The OMPD aims to incentivize the development of treatments for rare diseases, offering benefits like market exclusivity and protocol assistance.

PharmAla Biotech to Supply LaNeo MDMA for Clinical Trials at Mt. Sinai, Harvard, and Johns Hopkins

PharmAla Biotech will supply its GMP LaNeo MDMA to Mt. Sinai Health System for a clinical trial, supporting research into MDMA-assisted therapy.
Harvard Medical School's McLean Hospital has contracted PharmAla to provide MDMA for a clinical trial focused on borderline personality disorder.

FDA Approves Tepylute, a Ready-to-Dilute Thiotepa Formulation, for Breast and Ovarian Cancer

The FDA has approved Tepylute, a ready-to-dilute formulation of thiotepa, for treating breast and ovarian cancer, addressing limitations of the previous powder form.
Tepylute simplifies drug preparation, enhances dosing accuracy, and reduces healthcare personnel's exposure to this hazardous drug during handling.

FDA Accepts Shorla Oncology's NDA for Oral Liquid SH-201 in Leukemia and Other Cancers

The FDA has accepted Shorla Oncology's New Drug Application (NDA) for SH-201, an oral liquid formulation designed to treat specific types of leukemia and other cancers.
SH-201 aims to provide an alternative treatment option for patients who lack access to an oral liquid formulation, addressing a significant unmet need in cancer therapy.

Reference News

[1]
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
globenewswire.com · Oct 8, 2024

PharmAla Biotech contracted to supply MDMA for a clinical trial at the University of Texas, San Antonio, aiming to devel...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy